These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15122733)

  • 1. The role of the unblinded sponsor statistician.
    Snapinn S; Cook T; Shapiro D; Snavely D
    Stat Med; 2004 May; 23(10):1531-3. PubMed ID: 15122733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
    Ellenberg SS; George SL
    Stat Med; 2004 May; 23(10):1503-5. PubMed ID: 15122727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A major trial needs three statisticians: why, how and who?
    Pocock SJ
    Stat Med; 2004 May; 23(10):1535-9. PubMed ID: 15122734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The statistician and the data monitoring committee.
    D'Agostino RB
    Stat Med; 2004 May; 23(10):1501-2. PubMed ID: 15122726
    [No Abstract]   [Full Text] [Related]  

  • 7. What is the appropriate role of the trial statistician in preparing and presenting interim findings to an independent Data Monitoring Committee in the U.S. Cancer Cooperative Group setting?
    Bryant J
    Stat Med; 2004 May; 23(10):1507-11. PubMed ID: 15122728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Playing safe and preserving integrity: making the FDA model work.
    Wittes J
    Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential for bias in reporting of industry-sponsored clinical trials.
    Pyke S; Julious SA; Day S; O'Kelly M; Todd S; Matcham J; Seldrup J
    Pharm Stat; 2011; 10(1):74-9. PubMed ID: 21275037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary.
    Snapinn S
    Pharm Stat; 2011; 10(1):83-4. PubMed ID: 21275040
    [No Abstract]   [Full Text] [Related]  

  • 12. Access to data from clinical trials sponsored by pharmaceutical companies.
    West R
    Addiction; 2007 May; 102(5):682-3. PubMed ID: 17493100
    [No Abstract]   [Full Text] [Related]  

  • 13. Research review boards dogged by criticism.
    Ledford H
    Nature; 2009 Apr; 458(7238):557. PubMed ID: 19340042
    [No Abstract]   [Full Text] [Related]  

  • 14. Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics.
    Campbell MJ
    Pharm Stat; 2011; 10(1):80-1. PubMed ID: 21275038
    [No Abstract]   [Full Text] [Related]  

  • 15. Registering clinical trials in India.
    Bhatt A; Sewlikar S
    Natl Med J India; 2006; 19(1):1-3. PubMed ID: 16570676
    [No Abstract]   [Full Text] [Related]  

  • 16. Industry-sponsored pharmaceutical trials and research ethics boards: are they cloaked in too much secrecy?
    Ferris LE
    CMAJ; 2002 May; 166(10):1279-80. PubMed ID: 12041844
    [No Abstract]   [Full Text] [Related]  

  • 17. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Constraints on publication rights in industry-initiated clinical trials--secondary publication].
    Gøtzsche PC; Hróbjartsson A; Johansen HK; Haahr MT; Altman DG; Chan AW
    Ugeskr Laeger; 2006 Jun; 168(25):2467-9. PubMed ID: 16824372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to construct an optimal interim report: What the data monitoring committee does and doesn't need to know.
    Neaton JD; Grund B; Wentworth D
    Clin Trials; 2018 Aug; 15(4):359-365. PubMed ID: 29552920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Industry money skews drug overviews.
    Giles J
    Nature; 2005 Sep; 437(7058):458-9. PubMed ID: 16177748
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.